Experimental treatments of lymphedema have centred around delivery of lymphangiogenic growth factor such as vascular endothelial growth factor‐C (VEGF‐C); however, these efforts have been largely abandoned due to equivocal outcomes in clinical trials.14, 15, 16, 17, 18. The gene discussed is VEGFC; the disease is lymphedema.